58 / 1544
Follow-up (median 54 months; range: 27-79
months)
3 locoregional
relapses
5-year:
97% LC
57% PFS
68% OS
MVA: R1 resection (p=0.03)
ypN2 disease (p=0.04)
UVA: adjuvant chemotherapy (p=0.04)
MVA: R1 resection (p=0.03)
ypN2 disease (p=0.04)
UVA: adjuvant chemotherapy (p=0.04)
ypT3-4 tumor (p=0.01)
Dworak grade 0-2 (p=0.03)
21
De Ridder and Engels et al, Int J Radiat Oncol Biol Phys and Radiother Oncol 2008 - 2014